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Cutaneous leishmaniasis (CL) is associated with chronic inﬂammation and ulceration of
the skin. Tissue macrophages serve as host cells and immune activation is necessary for
parasite clearance. The balance between immune-mediated tissue destruction and suc-
cessful clearance of infection is delicate and ulceration has been proposed to be a result of
inﬁltration of activated immune cells into the skin. FasL and TRAIL play a dual role in skin
homeostasis through induction of apoptosis as well as proinﬂammatory signaling. During
leishmaniasis, dysregulation of both FasL andTRAIL has been described by us and others
but the resulting pathogenic effects in the skin during human leishmaniasis are not fully
elucidated.Targeting disease speciﬁc immune deviations has proven to be a promising new
approach for the therapy of autoimmune diseases. Potentially, targeting FasL or TRAIL in
combination with microcidals could offer a future treatment strategy to reduce the disﬁg-
uring immunopathology associated with CL. In this mini review we will discuss how FasL
and TRAIL-induced signaling may inﬂuence on the extent of tissue inﬂammation and the
efﬁcacy of parasite clearance in leishmaniasis.
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LEISHMANIA INFECTION OF THE SKIN CAUSE CHRONIC
TISSUE INFLAMMATION AND ULCERATION
Human leishmaniasis of epithelial surfaces presents with a
plethora of clinical manifestations – from asymptomatic infection
to chronic skin ulcers or devastating ulceration of mucous sur-
faces. Cutaneous leishmaniasis (CL) in the OldWorld is caused by
Leishmaniamajor, L. tropica, andL. aethiopica and careful histolog-
ical studies have elucidated the patterns of inﬂammation in these
lesions (Gaafar et al., 1995, 1999; Connor et al., 1997). Different
subspecies of Leishmania are associated with heterogeneous cuta-
neous manifestations but large clinical variations are also noted in
skin pathology caused by the same species of Leishmania. This
is exempliﬁed by L. aethiopica infection that induces localized
CL (LCL) or diffuse CL (DCL; Figure 1). LCL is characterized
by erosive ulcers and a strong T cell-mediated response (Akuffo
et al., 1987) which typically results in spontaneous healing within
a year, scar formation, and solid protection against re-infection
(Lemma et al., 1969). In contrast, DCL is linked to non-ulcerative
chronic nodular disease with abundant parasitic inﬁltration of
the dermal compartment of the skin and antigen-speciﬁc T cell
unresponsiveness (Nilsen and Mshana, 1987). In the Americas,
L. braziliensis cause devastating mucocutaneous lesions as well as
diffuse and ulcerating CL. L. braziliensis infection can also lead to
disseminated CL with a high number of ulcerated lesions spread
over the body at large devoid of detectable parasites (Costa et al.,
1986; Carvalho et al., 1994; Turetz et al., 2002). Patients affected
by disseminated cutaneous L. braziliensis infection show effective
antileishmanial T cell responses in circulating lymphocytes and
histological studies proposed pronounced T cell inﬁltration into
the affected skin (Leopoldo et al., 2006; Machado et al., 2011).
Ulceration and tissue destruction in CL seems to be mainly a con-
sequence of immune activation evoked by the infection rather
than a direct effect of the infectious burden of parasites although
deﬁnite proofs of this hypothesis has not been shown to date.
Nevertheless, a low infectious burden in combination with an efﬁ-
cient antileishmanial T cell response is detected in disseminating
or localized L. braziliensis-induced CL or L. aethiopica-induced
LCL and is linked to ulcerative disease. On the other hand, L.
aethiopica-induced DCL, with a high infectious burden and inef-
ﬁcient T cell responses, is linked to non-ulcerative disease. One
obvious future treatment strategy would be to try to modulate the
immune response to Leishmania so that the antileishmanial effects
are maximized but tissue destruction minimized.
FasL AND TRAIL SIGNALING LEAD TO APOPTOSIS OR
PRODUCTION OF PROINFLAMMATORY MEDIATORS
FasL and TRAIL (tumor necrosis factor-related apoptosis induc-
ing ligand) are death receptor ligands signaling through Fas, and
TRAIL R1-4, respectively (Figure 2A). Fas, as well as TRAIL-R1
and TRAIL-R2 contain a functional intracellular death domain
and may induce apoptosis but also alternative signals via NF-κB
andMAPK activation (Falschlehner et al., 2007; Peter et al., 2007).
TRAIL-R3 lack an intracellular cytoplastic domain and TRAIL-
R4 contains an incomplete intracellular death domain but may
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FIGURE 1 | Histological hallmarks of diffuse and localized cutaneous
leishmaniasis caused by L. aethiopica. (Top) Neutrophils, dendritic
cells, and tissue macrophages are targets for infective Leishmania
promastigotes and are present in the healthy skin. (Bottom) L. aethiopica
cause non-ulcerative diffuse cutaneous leishmaniasis (DCL) or ulcerative
localized cutaneous leishmaniasis (LCL). In non-ulcerative DCL (left),
epidermis is intact and a large number of tissue macrophages packed
with Leishmania amastigotes are present in dermis and the lymphocyte
inﬁltrate is sparse as compared to ulcerative LCL (right). In ulcerative
disease, apoptotic keratinocytes are present in the ulcerated epidermis.
Epidermal hyperplasia and proliferating keratinocytes surround the
ulcer and a dense inﬂammatory inﬁltrate is present in the dermal
compartment. The number of infected tissue macrophages
is low.
induce proinﬂammatory signaling through NF-κB (Falschlehner
et al., 2007). Fas regulates immune homeostasis and tolerance via
inducing apoptosis of activated T, B, and dendritic cells (DCs), as
suggested by the lymphoproliferative diseases associated with Fas
or FasL mutations and by studies using targeted Fas deletion on
T, B, and DCs (Stranges et al., 2007; Hao et al., 2008; Mabrouk
et al., 2008; Turbyville and Rao, 2010). By killing APCs, FasL
might decrease bystander T cell activation and in addition Fas can
serve as a molecular break for T cell responses by complement-
ing the effects of Bim to eliminate activated T cells (Hughes et al.,
2008). Death receptor-induced apoptosis thus regulates turnover
of effector cells during immune responses and additionally, due
to FasL and TRAIL being expressed by activated T, NKT, and NK
cells, it can eliminate cells infected by various pathogens. Death
receptor-induced apoptosis can contribute to bystander apoptosis
in inﬂamed tissues thereby increasing disease pathogenesis. Such
activity is well studied during HIV infection where FasL, TNF, and
TRAIL-mediated apoptosis have all been implicated in the deple-
tion of non-infected T lymphocytes (Gougeon, 2003). FasL and
TRAIL have also been shown to contribute tomemory B cell apop-
tosis, possibly contributing to the decreased serological memory
(Moir and Fauci, 2009; van Grevenynghe et al., 2011).
Non-apoptotic signaling activities of Fas stimulate T cell pro-
liferation, induce proinﬂammatory responses in various immune
cells, promote neuronal tissue remodeling, liver regeneration,
and tumor progression (Peter et al., 2007). Apoptotic and
non-apoptotic signals are probably occurring concomitantly in
response to death receptor triggering, with the outcome deter-
mined by the activity of several other mechanisms inﬂuencing
apoptosis sensitivity. Speciﬁcally, DISC localization at the cell
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FIGURE 2 | FasL andTRAIL signaling in ulcerative cutaneous
leishmaniasis. (A) FasL andTRAIL signaling induce apoptosis or
proinﬂammatory signaling depending on the receptor expression on
the target cell. (Left) Fas is expressed as a homodimer on cell-surfaces.
Upon FasL ligation to trimerized Fas caspase activation leading to apoptosis
is initiated. Fas may also lead to NF-κb activation. sFas probably serves
as a negative modulator of FasL. The function of sFasL is debated and it
has been suggested that the concentration will determine if apoptosis
can be triggered through Fas by sFasL. (Right) Apoptosis is induced
throughTRAIL activation of TRAIL-R1 and -R2. TRAIL-R3 is a decoy receptor
and will not initiate intracellular signaling. Activation of TRAIL-R4 leads
to NK-κB activation. OPG is a soluble receptor bindingTRAIL and its
function has not been elucidated. (B) A model for keratinocyte
apoptosis in the ulcerative process of CL. Keratinocytes upregulate
Fas, TRAIL-R2, -R4, andTRAIL as a result of the inﬂammatory reaction
surrounding L. major -infected macrophages. FasL-expressingT cells and
TRAIL-expressing inﬂammatory cells accumulate at the site of L. major
infection. The Fas–FasL/Fas–sFasL andTRAIL/TRAIL-R interaction may
lead to keratinocyte apoptosis and ulceration as well as to activation
inducedT cell apoptosis.
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membrane, high c-FLIP expression or the activity of Toso have
been shown to increase stimulatory signals from death recep-
tors and the threshold for apoptosis (Lee et al., 1998; Peter et al.,
2007; Nguyen et al., 2011). In addition, the same cell types can
respond differently to death receptor triggering depending on
the stage of activation. Fas triggering can induce early apopto-
sis among activated T cells and enhanced proliferation of the
surviving T cells (Maksimow et al., 2003). Triggering Fas on non-
activated T cells of HIV-infected individuals can lead to apoptosis,
whereas the same signal contributed to strong activation of T cells
that received weak, otherwise ignorable TCR stimuli (Rethi et al.,
2008). In addition to activation or death decided at the level
of single cells, death receptor-induced apoptosis of one cell can
modulate the activities of others thereby playing a complex reg-
ulatory role during immune responses. As will be discussed later,
Fas-induced apoptosis of neutrophils during Leishmania infec-
tion can lead to macrophage activation or inactivation depending
on the host’s genetic background, which strongly inﬂuence the
immune response against the pathogen (Ribeiro-Gomes et al.,
2004, 2005).
FasL AND TRAIL SIGNALING IN SKIN HOMEOSTASIS
AND INFLAMMATION
Epidermis is a stratiﬁed epithelium mainly composed of ker-
atinocytes. It is separated from the underlying dermis by the
basal membrane and basal keratinocytes are susceptible to FasL
and TRAIL-induced apoptosis (Jansen et al., 2003; Vassina et al.,
2005). IFNγ renders keratinocytes more susceptible to death
receptor-induced apoptosis (Konur et al., 2005). TRAIL, as well
as TRAIL-R1, -R2, and -R4 are expressed in keratinocytes in the
healthy skin (Leverkus et al., 2000; Stander and Schwarz, 2005).
TRAIL induces apoptosis in IFNγ stimulated keratinocytes and
was shown to induce apoptosis in proliferating but not differ-
entiating human keratinocytes (Jansen et al., 2003). To further
show the complex role of TRAIL signaling in the skin, TRAIL
was shown to induce caspase-dependent differentiationof primary
keratinocytes (Wu et al., 2011).
FasL-mediated killing of IFNγ sensitized keratinocytes by
T cells has been shown in the skin during atopic dermatitis
(AD). In this setting, apoptotic keratinocytes were shown to
release T cell chemoattractants. Thus, a loop of signaling between
inﬁltrating, FasL-expressing T cells and activated, Fas-expressing
keratinocytes was suggested which ultimately increased the num-
ber of inﬂammatory T cells in eczematous skin (Trautmann et al.,
2000). FasL signaling has also been shown to induce produc-
tion of several proinﬂammatory cytokines such as TNFα, IL1β,
and IL-6 and activation of the epidermal growth factor receptor
in keratinocytes in AD (Iordanov et al., 2005). FasL driven pro-
duction of proinﬂammatory cytokines could in part explain the
increased proliferation of keratinocytes which has been reported
in many dermatoses including CL. TRAIL-expressing CD4+ and
CD8+ T cells are present in dermis during AD (Vassina et al.,
2005). TRAIL-expressing dermal DCs (Zaba et al., 2010) and
upregulation of TRAIL-R1 and -R2 has been shown in the
psoriatic skin (Goto and Lindoso, 2010). Nickel renders basal ker-
atinocytes sensitive to TRAIL-mediated apoptosis through upreg-
ulation of TRAIL-R1 and -R2 in contact dermatitis toward nickel
(Schmidt et al., 2010). Despite many descriptive studies showing
the presence of TRAIL-expressing cells in the skin during inﬂam-
mation, the consequences of such dysregulation are still at large
unknown.
Alterations of Fas and FasL expression in keratinocytes (Viard
et al., 1998) and in the effector T cell compartment (Abe et al.,
2003) leading to keratinocyte death and ulceration has been
described in toxic epidermal necrolysis (TEN). Recently, sTRAIL
secreted by dermal DCs present in TEN lesions was shown to
induce keratinocyte apoptosis (deAraujo et al., 2011). Thus, a syn-
ergistic killing of keratinocytes by FasL released from inﬁltrating
T cells and TRAIL released by inﬁltratingDCs could occur in TEN.
Intravenous immunoglobulins (IVIG) exhibits a broad spectrum
of immunoregulatory activities and both activation and inhibi-
tion of Fas signaling (Prasad et al., 1998; Viard et al., 1998) has
been ascribed IVIG and systemic treatment with IVIG-containing
Fas-blocking antibodies limited the ulcerative process during TEN
(Abe et al., 2003). To date, direct targeting of FasL signaling has
not been tested in man during TEN.
DYSREGULATION OF FasL AND TRAIL AND THEIR
RECEPTORS DURING HUMAN LEISHMANIASIS
Leishmania promastigotes are rapidly ingested by neutrophils
and DCs present in the healthy skin (Laskay et al., 2008; Ng
et al., 2008; Peters et al., 2008). In visceral leishmaniasis (VL),
the parasites spreads from the skin to draining lymph nodes
and further on throughout the reticuloendothelial organs in the
body including the spleen, the liver, and the bone marrow. VL
leads to a systemic and potentially lethal infection. Fas and FasL
are highly expressed on spleen-derived leukocytes but not on
peripheral blood mononuclear cells during VL, suggesting local-
ized increase in Fas/FasL expression only at the site of infection
(Eidsmo et al., 2002).
In CL, the infection is mainly conﬁned to the skin and within
a few weeks after infection tissue macrophages serves as the
main host cells. Localized chronic tissue inﬂammation arises and
Leishmania-laden macrophages need to be activated through sig-
nals from inﬁltrating leukocytes, primarily T cells but also B cells
and neutrophils, to clear infection. Keratinocyte proliferation and
activationwith an upregulation of activationmarkers such asHLA
DR is noted together withmarked epidermal hyperplasia, necrosis,
and apoptosis (ElHassan et al., 1995; Gaafar et al., 1999).
We and others have shown that Fas and FasL is upregulated
in the skin in L. major and L. aethiopica-induced ulcerative CL
(Mustafa et al., 2001; Eidsmo et al., 2005, 2007; Tasew et al., 2010;
Table 1) and apoptotic keratinocytes surround ulcers (Eidsmo
et al., 2005). In the case of L. aethiopica-induced CL, we have
shown increased number of dermal FasL-expressing cells in ulcer-
ating as compared to non-ulcerative lesions. In ulcerative CL,
the number of apoptotic keratinocytes correlates with the num-
ber of FasL-expressing dermal cells (Eidsmo et al., 2005; Tasew
et al., 2010). In agreement with our ﬁndings, increased numbers
of FasL-expressing cells were detected in L. braziliensis-induced
LCL and DCL (Carneiro et al., 2009) and the number of apop-
totic cells correlated to the number of FasL-expressing cells in
ulcerative LCL. In addition, increased expression of Fas and
FasL was recently shown in oral mucosal leishmaniasis caused by
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Table 1 | Increased expression of FasL,TRAIL,TRAIL-R2, and -R4 at the
site of infection during ulcerative leishmaniasis.
Healthy skin Ulcerative CL Non-ulcerative CL
Epidermis
Apoptosis Absent High Low
Proliferation Low High Low
FasL Absent Absent Absent
Fas Moderate High High
TRAIL Low High Moderate
TRAIL-R1 Moderate Moderate Moderate
TRAIL-R2 Low High Moderate
TRAIL-R3 High High Not done
TRAIL-R4 Absent Moderate Not done
Dermis
Apoptosis Low High Low
Proliferation Low Low Low
FasL Absent High Low
Fas Low High High
TRAIL Absent High Moderate
TRAIL-R1 Absent Low Low
TRAIL-R2 Absent Moderate Low
Expression of FasL andTRAIL and their receptors togetherwith detection of apop-
tosis was visualized in human skin biopsies obtained from L. major-induced CL in
Iran and L. aethiopica-induced CL in Ethiopia and compared to endemic healthy
controls. A total of 51 biopsies were assessed: healthy individuals (n = 11),
ulcerative LCL induced by L. major (n = 8), L. aethiopica (n = 19), and non-
ulcerative DCL induced by L. aethiopica (n = 13; Eidsmo et al., 2005, 2007;
Tasew et al., 2010).
L. braziliensis (Palmeiro et al., 2012). In ulcerative CL induced by
L. major, TRAIL as well as the pro-apoptotic receptor TRAIL-R2
and the proinﬂammatory receptor TRAIL-4 were upregulated in
infected skin as compared to healthy controls (Figure 2B; Eidsmo
et al., 2007). In L. aethiopica-induced CL, higher levels of TRAIL
and TRAIL-R2 were detected in patients as compared to healthy
control and ulcerative LCL had higher levels of TRAIL and TRAIL-
R2 as compared to non-ulcerative DCL (Eidsmo et al., 2007;
Tasew et al., 2010) and (unpublished observations; Table 1 and
Figure 2B).
To test if the observed increased expression of FasL and TRAIL-
were indeed involved in ulceration during CL, we performed
in vitro experiments using supernatants derived from L. major and
L. aethiopica stimulated PBMCs that contained high levels of sFasL
and sTRAIL. Primary keratinocytes and the keratinocyte cell line
HaCaT exposed to sFasL- and sTRAIL-containing supernatants
underwent apoptosis and this could be prevented by adding
FasL and TRAIL neutralizing antibodies to the keratinocytes
prior to exposure to supernatants. Interestingly, when strains
of L. aethiopica isolated from patients with non-ulcerative DCL
were used, keratinocyte apoptosis was not induced (Eidsmo et al.,
2005, 2007; Tasew et al., 2010). To study the full consequences of
FasL and TRAIL signaling during complex tissue infection and
inﬂammation, we turned to an animal model of ulcerative CL.
L. aethiopica inoculation inmice does not lead to productive infec-
tion or ulcerative disease. Murine CL can be obtained by L. major
infection where in our hands the parasite strain Friedlin leads to
ulcerative infection in BALB/c and the parasite strain LV39 leads to
non-ulcerative infection. Thus, we have used L. major as a model
organism to induce CL in mice as discussed below.
REGULATION OF NEUTROPHIL CHEMOTAXIS BY
Fas ACTIVATION IN LEISHMANIA INFECTION
During the chronic phase of CL, large numbers of neutrophils are
present at the site of infection (Doerr and Seifert, 1995). Neu-
trophils age rapidly in the circulation and are constantly removed
by macrophages in bone marrow, spleen, and liver (Furze and
Rankin, 2008). Their activation leads to rapid apoptosis in which
death receptors and Bcl-2 family member proteins play a role
(Croker et al., 2011). Neutrophils serve as a ﬁrst host during Leish-
mania infection and it has been shown in several settings that their
spontaneous apoptosis is delayed upon infection and that infected,
apoptotic neutrophils can serve as Trojan horses allowing the par-
asite a silent entry into tissue macrophages serving as the deﬁnite
host (Aga et al., 2002; van Zandbergen et al., 2004).
FasL contributes to massive apoptosis of macrophages exposed
to L. major in BALB/c mice and to the production of the
chemokines CXCL1 and CCL3, both with neutrophil chemoat-
tractant activity (Ribeiro-Gomes et al., 2005). Similarly to
macrophages, Fas triggering on the surface of DCs, keratinocytes,
and a subset of NKT cells induced the production of neutrophil
chemoattractants (Giroux and Denis, 2005; Guo et al., 2005; Far-
ley et al., 2006). The Fas/FasL molecule pair can thus serve as an
accelerator of inﬂammation in addition to inducing apoptosis in
various cell types. The FasL-induced neutrophil inﬁltration has
several consequences. In addition to increasing pathogen clear-
ance, the phagocytic cells might be important for the removal
of apoptotic cells that accumulate as the result of the increased
Fas activation. Apoptotic neutrophils can also initiate tissue
repair mechanisms in macrophages, partly by inducing TGFβ
secretion, which, on the other hand, facilitate Leishmania repli-
cation in macrophages (Afonso et al., 2008). In FasL-deﬁcient gld
mice, both macrophage apoptosis and chemokine production was
reduced aswell as the extravasationof neutrophils (Ribeiro-Gomes
et al., 2005). Similarly, FasL neutralization using antibodies dur-
ing ulcerative L. major (strain Friedlin V1) infection in BALB/c
mice resulted in decreased neutrophil inﬁltration into infected
skin (Tasew et al., 2010). The number of lesional neutrophils was
approximately sixfold lower in a non-ulcerative model of L. major
infection induced by the parasite-strain LV39. FasL neutralization
in LV39-induced infection further reduced the number of lesional
neutrophils (Tasew et al., 2010).
MODULATION OF MACROPHAGE RESPONSE TO
LEISHMANIA BY APOPTOTIC NEUTROPHILS
Neutrophils eliminate infecting pathogens via phagocytosis or
by secreting reactive oxygen species, inﬂammatory cytokines,
and chemokines and thereby increasing tissue inﬂammation. In
addition, activated neutrophils can release a network formed of
DNA and various granule proteins, called neutrophil extracellular
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traps, which can kill infecting pathogens including Leishma-
nia (Guimaraes-Costa et al., 2009). Neutrophil responses are
under tight regulation and the activation of these cells is rapidly
followed by apoptosis, partly induced by Fas triggering. Apop-
totic neutrophils can increase the activation of macrophages or
DCs (Majai et al., 2010) and their phagocytozed material can
be used as a source of pathogen-derived peptides for antigen
presentation. It has been shown that apoptotic neutrophils reg-
ulate macrophage responses to Leishmania infection differently
in BALB/c or C57BL/6 mice. In BALB/c mice, more sensitive to
Leishmania infection, apoptotic neutrophils inhibit macrophage
activation and facilitate pathogen replication in the cells via
a PGE2 and TGF-β-dependent pathway (Ribeiro-Gomes et al.,
2005). Interestingly, the absence of FasL fundamentally changed
the role of neutrophils in the regulation of macrophage responses
to Leishmania infection. The absence of FasL altered kinetics and
probably the mechanism of apoptosis, and in this case neutrophils
increased parasite clearance by macrophages via a NO-dependent
mechanism (Ribeiro-Gomes et al., 2005).
In C57BL/6 mice, more resistant to Leishmania infection,
apoptotic neutrophils increased parasite killing by macrophages
through a neutrophil elastase-dependent induction of TNFα
secretion (Ribeiro-Gomes et al., 2004). PGE2 and TGFβ, the
neutrophil-induced factors in BALB/c mice that promote parasite
growth in macrophages, were not induced during neutrophil–
macrophage interactions in the C57BL/6 model. Thus, FasL turns
neutrophils to suppressors of Leishmania clearance in BALB/c
mice which was reﬂected by the ﬁnding that in vivo depletion
of neutrophils decreased parasite load in wild-type (WT) but
increased parasite load in gld mice (Ribeiro-Gomes et al., 2005). In
C57BL/6 mice, in line with the macrophage stimulatory functions
of neutrophils, granulocyte depletion led to increased parasite load
(Ribeiro-Gomes et al., 2004).
Fas-MEDIATED MACROPHAGE APOPTOSIS MAY
CONTRIBUTE TO PARASITE CLEARANCE
In contrast to BALB mice, Fas or FasL deﬁciency on MLR
and C57BL/6 background led to impaired parasite clearance
when a high number of parasites was inoculated subcutaneously
(Conceicao-Silva et al., 1998; Huang et al., 1998). Leishmania-
infected macrophages upregulated Fas and apoptosis sensitivity
in response to the Th1 cytokine IFNγ and to autocrine TNFα pro-
duction. It was suggested that Fas-mediated elimination of Leish-
mania-infected macrophages play an important role in decreasing
the parasite load (Conceicao-Silva et al., 1998). However, other
studies have shown that gld mice on a C57BL/6 background con-
trol infection as efﬁcient as WT control and that TNF, acting like
another death receptor ligand, plays an essential role in pathogen
clearance (Wilhelm et al., 2001, 2005). In these studies, the results
varied depending on the Leishmania strain used for infection,
indicating that the genetic background of both the host and the
pathogen can inﬂuence the contribution of death receptors in
the Leishmania-speciﬁc immune responses (Wilhelm et al., 2001;
Ritter et al., 2004).
SHORT-TERM INHIBITION OF FasL AND TRAIL SIGNALING
DECREASE ULCERATION IN BALB/c MICE INFECTED
WITH L. MAJOR
BALB/c serves as an ulcerative, non-healing model of CL and
C57BL/6 mice serve as a non-ulcerative but healing model of
CL. Thus, the characteristics of human CL are not completely
mimicked by the models available. To study the effect of FasL or
TRAIL neutralization during ulcerative CL, we utilized a model
of injecting a low-infectious dose of metacyclics into dermis in
BALB/c mice. Neutralization of both FasL and TRAIL inhibited
ulcer development and no effect on the infectious load in the skin
or draining lymph nodes was noted (Tasew et al., 2010). Interest-
ingly, FasL neutralization reduced neutrophil inﬁltration into the
skin during established infection, suggesting an additional proin-
ﬂammatory role of FasL in addition to direct keratinocyte killing.
FasL signaling resulting in recruitment of activated neutrophils
into dermis may lead to destruction of the basal membrane and
thus allow direct FasL-mediated killing of exposed keratinocytes
in vivo.
A majority of patients affected by CL will request treatment
despite the benign prognosis of the disease. The current treatment
regimes are primarily aimed at parasite elimination and many
will result in exacerbation of inﬂammation, tissue destruction,
and scar formation (Mishra et al., 2007; Goto and Lindoso, 2010).
Targeting speciﬁc immunemechanisms has proven to be a promis-
ing new approach for the therapy of cancer and autoimmune
diseases and could potentially be used to improve treatment
regimes of neglected tropical diseases including leishmaniasis. The
current revolution in the development of immunotherapeutics
could lead to novel effective treatments of neglected tropical dis-
eases. Skin diseases serves as an excellent model system to test
novel treatment regimes as the pathology and disease develop-
ment can be followed by the naked eye. It has been suggested that
TNFα-blocking antibodies could reduce tissue pathology during
CL (Oliveira et al., 2011) and that inhibition of tyrosine kinases
during VL could improve treatment efﬁcacy (Dalton and Kaye,
2010; Dalton et al., 2010). We suggest that inhibition of reducing
FasL and TRAIL signaling at the site of infection in combina-
tion with leishmanicidals could in theory reduce the chronic
inﬂammation and the ulcerative process and subsequent scar
formation.
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